The effect of COVID rehabilitation for ongoing symptoms Post HOSPitalisation with COVID-19 (PHOSP-R): protocol for a randomised parallel group controlled trial on behalf of the PHOSP consortium
Enya Daynes,
Molly Baldwin,
Neil J. Greening,
Thomas Yates,
Nicolette C. Bishop,
George Mills,
Matthew Roberts,
Malik Hamrouni,
Tatiana Plekhanova,
Ioannis Vogiatzis,
Carlos Echevarria,
Rashmita Nathu,
Hamish J. C. McAuley,
Lorna Latimer,
Jennifer Glennie,
Francesca Chambers,
Ruth Penfold,
Emily Hume,
Dimitrios Magaritis,
Charikleia Alexiou,
Sebastian Potthoff,
Mitchell James Hogg,
Catherine Haighton,
Bethany Nichol,
Olivia C. Leavy,
Matthew Richardson,
Omer Elneima,
Amisha Singapuri,
Marco Sereno,
Ruth M. Saunders,
Victoria C. Harris,
Claire M. Nolan,
Charlotte Bolton,
Linzy Houchen-Wolloff,
Ewen M. Harrison,
Nazir Lone,
Jennifer Quint,
James D. Chalmers,
Ling-Pei Ho,
Alex Horsley,
Michael Marks,
Krisnah Poinasamy,
Betty Ramen,
Louise V. Wain,
Christopher Brightling,
William D.-C. Man,
Rachael Evans,
Sally J. Singh
Affiliations
Enya Daynes
NIHR Leicester Biomedical Research Centre-Respiratory
Molly Baldwin
NIHR Leicester Biomedical Research Centre-Respiratory
Neil J. Greening
NIHR Leicester Biomedical Research Centre-Respiratory
Thomas Yates
NIHR Leicester Biomedical Research Centre- Diabetes
Nicolette C. Bishop
National Centre for Sport and Exercise Medicine, School of Sport, Exercise and Health Sciences, Loughborough University
George Mills
NIHR Leicester Biomedical Research Centre-Respiratory
Matthew Roberts
NIHR Leicester Biomedical Research Centre-Respiratory
Malik Hamrouni
NIHR Leicester Biomedical Research Centre-Respiratory
Tatiana Plekhanova
NIHR Leicester Biomedical Research Centre- Diabetes
Ioannis Vogiatzis
Faculty of Health and Life Sciences, Northumbria University Newcastle
Carlos Echevarria
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Rashmita Nathu
NIHR Leicester Biomedical Research Centre-Respiratory
Hamish J. C. McAuley
NIHR Leicester Biomedical Research Centre-Respiratory
Lorna Latimer
NIHR Leicester Biomedical Research Centre-Respiratory
Jennifer Glennie
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Francesca Chambers
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Ruth Penfold
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Emily Hume
Faculty of Health and Life Sciences, Northumbria University Newcastle
Dimitrios Magaritis
Faculty of Health and Life Sciences, Northumbria University Newcastle
Charikleia Alexiou
Faculty of Health and Life Sciences, Northumbria University Newcastle
Sebastian Potthoff
Department of Social Work, Education, and Community Wellbeing, Northumbria University Newcastle
Mitchell James Hogg
Faculty of Health and Life Sciences, Northumbria University Newcastle
Catherine Haighton
Faculty of Health and Life Sciences, Northumbria University Newcastle
Bethany Nichol
Faculty of Health and Life Sciences, Northumbria University Newcastle
Olivia C. Leavy
Department of Health Sciences, University of Leicester
Matthew Richardson
NIHR Leicester Biomedical Research Centre-Respiratory
Omer Elneima
NIHR Leicester Biomedical Research Centre-Respiratory
Amisha Singapuri
NIHR Leicester Biomedical Research Centre-Respiratory
Marco Sereno
NIHR Leicester Biomedical Research Centre-Respiratory
Ruth M. Saunders
NIHR Leicester Biomedical Research Centre-Respiratory
Victoria C. Harris
NIHR Leicester Biomedical Research Centre-Respiratory
Claire M. Nolan
College of Health, Medicine and Life Sciences, Brunel University
Charlotte Bolton
School of Medicine, The University of Nottingham
Linzy Houchen-Wolloff
NIHR Leicester Biomedical Research Centre-Respiratory
Ewen M. Harrison
Department of Health Sciences, University of Leicester
Nazir Lone
Centre for Medical Informatics, The Usher Institute, University of Edinburgh
Jennifer Quint
National Heart and Lung Institute, Imperial College London
James D. Chalmers
Royal Infirmary of Edinburgh, NHS Lothian
Ling-Pei Ho
MRC Human Immunology Unit, University of Oxford
Alex Horsley
Division of Infection, Immunity & Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester
Michael Marks
Hospital for Tropical Diseases, University College London Hospitals
Krisnah Poinasamy
Asthma UK and British Lung Foundation
Betty Ramen
Radcliffe Department of Medicine, University of Oxford
Louise V. Wain
NIHR Leicester Biomedical Research Centre-Respiratory
Christopher Brightling
NIHR Leicester Biomedical Research Centre-Respiratory
William D.-C. Man
Harefield Respiratory Research Group, Guy’s and St Thomas’ NHS Foundation Trust
Rachael Evans
NIHR Leicester Biomedical Research Centre-Respiratory
Sally J. Singh
NIHR Leicester Biomedical Research Centre-Respiratory
Abstract Introduction Many adults hospitalised with COVID-19 have persistent symptoms such as fatigue, breathlessness and brain fog that limit day-to-day activities. These symptoms can last over 2 years. Whilst there is limited controlled studies on interventions that can support those with ongoing symptoms, there has been some promise in rehabilitation interventions in improving function and symptoms either using face-to-face or digital methods, but evidence remains limited and these studies often lack a control group. Methods and analysis This is a nested single-blind, parallel group, randomised control trial with embedded qualitative evaluation comparing rehabilitation (face-to-face or digital) to usual care and conducted within the PHOSP-COVID study. The aim of this study is to determine the effectiveness of rehabilitation interventions on exercise capacity, quality of life and symptoms such as breathlessness and fatigue. The primary outcome is the Incremental Shuttle Walking Test following the eight week intervention phase. Secondary outcomes include measures of function, strength and subjective assessment of symptoms. Blood inflammatory markers and muscle biopsies are an exploratory outcome. The interventions last eight weeks and combine symptom-titrated exercise therapy, symptom management and education delivered either in a face-to-face setting or through a digital platform ( www.yourcovidrecovery.nhs.uk ). The proposed sample size is 159 participants, and data will be intention-to-treat analyses comparing rehabilitation (face-to-face or digital) to usual care. Ethics and dissemination Ethical approval was gained as part of the PHOSP-COVID study by Yorkshire and the Humber Leeds West Research NHS Ethics Committee, and the study was prospectively registered on the ISRCTN trial registry (ISRCTN13293865). Results will be disseminated to stakeholders, including patients and members of the public, and published in appropriate journals. Article summary Strengths and limitations of this study • This protocol utilises two interventions to support those with ongoing symptoms of COVID-19 • This is a two-centre parallel-group randomised controlled trial • The protocol has been supported by patient and public involvement groups who identified treatments of symptoms and activity limitation as a top priority